Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

Ligand Pharmaceuticals Incorporated (LGND)

  • Business News
  • Nov. 06, 2025, 12:00 UTC
  • 19
  • 1 comments

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

Market reaction Comment Full text

Viatris Inc (VTRS)

  • Business News
  • Nov. 06, 2025, 11:59 UTC
  • 17
  • 1 comments

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

Market reaction Comment Full text

Protalix BioTherapeutics Inc. (PLX)

  • Business News
  • Nov. 06, 2025, 11:50 UTC
  • 15
  • 1 comments

Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025

Market reaction Comment Full text

Teleflex Incorporated (TFX)

  • Business News
  • Nov. 06, 2025, 11:45 UTC
  • 16
  • 1 comments

Teleflex Announces Quarterly Dividend

Market reaction Comment Full text

Eli Lilly and Company (LLY)

  • Business News
  • Nov. 06, 2025, 11:45 UTC
  • 16
  • 1 comments

Lillys selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight

Market reaction Comment Full text

Insulet Corporation (PODD)

  • Business News
  • Nov. 06, 2025, 11:30 UTC
  • 13
  • 1 comments

Insulet Reports Third Quarter 2025 Results

Market reaction Comment Full text

Stevanato Group SpA (STVN)

  • Business News
  • Nov. 06, 2025, 11:30 UTC
  • 12
  • 1 comments

Stevanato Group Reports Revenue of €303.2 Million for the Third Quarter of 2025

Market reaction Comment Full text

Teleflex Incorporated (TFX)

  • Business News
  • Nov. 06, 2025, 11:30 UTC
  • 14
  • 1 comments

Teleflex Reports Third Quarter Financial Results and Full Year 2025 Outlook

Market reaction Comment Full text

Aveanna Healthcare Holdings Inc (AVAH)

  • Business News
  • Nov. 06, 2025, 11:30 UTC
  • 13
  • 1 comments

Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2025 Outlook

Market reaction Comment Full text

4D Molecular Therapeutics (FDMT)

  • Business News
  • Nov. 06, 2025, 11:23 UTC
  • 10
  • 1 comments

4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

Market reaction Comment Full text
  • Previous
  • 797
  • 798
  • 799
  • 800
  • 801
  • Next

Search

News categories

  • Technical Exchange News(10969)
  • Event(2452)
  • SEC News(193679)
  • FDA Approval(10304)
  • Company Report(721)
  • Business News(126056)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin